Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2

Journal of Autoimmunity

Volumn 53, Issue C, 2014, Pages 26-32

  Holder, Beth S ^a,b   Grant, Charlotte R ^a   Liberal, Rodrigo ^a,c   Ma, Yun ^a   Heneghan, Michael A ^a   Mieli Vergani, Giorgina ^a   Vergani, Diego ^a   Longhi, Maria Serena ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c University of Porto   (Portugal)

Author keywords

Autoimmune liver disease; Liver autoantigen; Regulatory T cell immunotherapy; Stability; Tolerance

Indexed keywords

AZATHIOPRINE; CD39 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CYTOCHROME P450 2D6; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PREDNISOLONE; RAPAMYCIN; RETINOIC ACID; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE HEPATITIS TYPE 2; CELL FUNCTION; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPLEMENTATION; TH17 CELL; ADOLESCENT; CLINICAL TRIAL; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; PATHOLOGY;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CYTOCHROME P-450 CYP2D6; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TRETINOIN;

EID: 84926407089     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.02.001     Document Type: Article

References (40)

1. Longhi M.S., Ma Y., Bogdanos D.P., Cheeseman P., Mieli-Vergani G., Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. JHepatol 2004, 41:31-37.
2. Longhi M.S., Hussain M.J., Mitry R.R., Arora S.K., Mieli-Vergani G., Vergani D., et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. JImmunol 2006, 176:4484-4491.
3. Ferri S., Longhi M.S., De Molo C., Lalanne C., Muratori P., Granito A., et al. Amultifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010, 52:999-1007.
4. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32.
5. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
6. Hippen K.L., Riley J.L., June C.H., Blazar B.R. Clinical perspectives for regulatory T cells in transplantation tolerance. Semin Immunol 2011, 23:462-468.
7. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Techmanska I., Juscinska J., et al. Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 2012, 35:1817-1820.
8. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. Invitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. JExp Med 2004, 199:1455-1465.
9. Tarbell K.V., Yamazaki S., Olson K., Toy P., Steinman R.M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. JExp Med 2004, 199:1467-1477.
10. Stephens L.A., Malpass K.H., Anderton S.M. Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg. Eur J Immunol 2009, 39:1108-1117.
11. Sagoo P., Ali N., Garg G., Nestle F.O., Lechler R.I., Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011, 3. 83ra42.
12. Manns M.P., Johnson E.F., Griffin K.J., Tan E.M., Sullivan K.F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. JClin Invest 1989, 83:1066-1072.
13. Muratori L., Parola M., Ripalti A., Robino G., Muratori P., Bellomo G., et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000, 46:553-561.
14. Ma Y., Bogdanos D.P., Hussain M.J., Underhill J., Bansal S., Longhi M.S., et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006, 130:868-882.
15. Longhi M.S., Hussain M.J., Bogdanos D.P., Quaglia A., Mieli-Vergani G., Ma Y., et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007, 46:472-484.
16. Longhi M.S., Hussain M.J., Kwok W.W., Mieli-Vergani G., Ma Y., Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011, 53:536-547.
17. Battaglia M., Stabilini A., Draghici E., Migliavacca B., Gregori S., Bonifacio E., et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 2006, 55:1571-1580.
18. Qu Y., Zhang B., Zhao L., Liu G., Ma H., Rao E., et al. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol 2007, 17:153-161.
19. Strauss L., Whiteside T.L., Knights A., Bergmann C., Knuth A., Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. JImmunol 2007, 178:320-329.
20. Elias K.M., Laurence A., Davidson T.S., Stephens G., Kanno Y., Shevach E.M., et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008, 111:1013-1020.
21. Wang J., Huizinga T.W., Toes R.E. De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid. JImmunol 2009, 183:4119-4126.
22. Mennechet F.J., Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107:4417-4423.
23. Longhi M.S., Ma Y., Mitry R.R., Bogdanos D.P., Heneghan M., Cheeseman P., et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. JAutoimmun 2005, 25:63-71.
24. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. JExp Med 2007, 204:1257-1265.
25. Longhi M.S., Liberal R., Holder B., Robson S.C., Ma Y., Mieli-Vergani G., et al. Inhibition of Interleukin-17 promotes differentiation of CD25(-) cells into stable t regulatory cells in patients with autoimmune hepatitis. Gastroenterology 2012, 142:1526-1535.
26. Longhi M.S., Meda F., Wang P., Samyn M., Mieli-Vergani G., Vergani D., et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology (Baltimore, Md) 2008, 47:581-591.
27. Hippen K.L., Merkel S.C., Schirm D.K., Nelson C., Tennis N.C., Riley J.L., et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant 2011, 11:1148-1157.
28. Jiang S., Golshayan D., Tsang J., Lombardi G., Lechler R.I. Invitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. Int Immunopharmacol 2006, 6:1879-1882.
29. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13:423-431.
30. Benson M.J., Pino-Lagos K., Rosemblatt M., Noelle R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation 2007, 1765-1774.
31. Elias K.M., Laurence A., Davidson T.S., Stephens G., Kanno Y., Shevach E.M., et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway 2008, 1013-1020.
32. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science (New York, NY) 2007, 317:256-260.
33. Wang J., Huizinga T.W.J., Toes R.E.M. De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid 2009, 4119-4126.
34. Scotta C., Esposito M., Fazekasova H., Fanelli G., Edozie F.C., Ali N., et al. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ Treg subpopulations. Haematologica 2012.
35. Iwata M., Eshima Y., Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol 2003, 15:1017-1025.
36. Van Y.-H., Lee W.-H., Ortiz S., Lee M.-H., Qin H.-J., Liu C.-P. All-trans retinoic acid inhibits type 1 Diabetes by T Regulatory (Treg)-Dependent suppression of interferon-γ-producing t-cells without affecting Th17 cells. Diabetes 2009, 58:146-155.
37. Fox C.J., Hammerman P.S., Thompson C.B. The Pim kinases control rapamycin-resistant T cell survival and activation 2005, 259-266.
38. Basu S., Golovina T., Mikheeva T., June C.H., Riley J.L. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. JImmunol 2008, 180:5794-5798.
39. Battaglia M., Stabilini A., Roncarolo M.-G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells 2005, 4743-4748.
40. Golovina T.N., Mikheeva T., Brusko T.M., Blazar B.R., Bluestone J.A., Riley J.L. Retinoic acid and rapamycin differentially affect and synergistically promote the exvivo expansion of natural human T regulatory cells. PloS one 2011, 6:e15868.